Trials / Completed
CompletedNCT00193245
Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
A Randomized Trial of Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with intravenous docetaxel in the second-line treatment of patients with non-small cell lung cancer.
Detailed description
Upon determination of eligibility, patients will be randomly assigned to one of two treatment arms: * Topotecan * Docetaxel For ever 2 patients treated, 1 will receive treatment A (Topotecan) and 1 will receive treatment B (Docetaxel). The study is not blinded so both the patient and the doctor will know which treatment has been assigned.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Topotecan | |
| DRUG | Docetaxel |
Timeline
- Start date
- 2000-11-01
- Primary completion
- 2005-10-01
- Completion
- 2009-01-01
- First posted
- 2005-09-19
- Last updated
- 2010-06-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00193245. Inclusion in this directory is not an endorsement.